595 related articles for article (PubMed ID: 14634792)
1. L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.
Tsurusawa M; Chin M; Iwai A; Nomura K; Maeba H; Taga T; Higa T; Kuno T; Hori T; Muto A; Yamagata M;
Cancer Chemother Pharmacol; 2004 Mar; 53(3):204-8. PubMed ID: 14634792
[TBL] [Abstract][Full Text] [Related]
2. Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961).
Grigoryan RS; Panosyan EH; Seibel NL; Gaynon PS; Avramis IA; Avramis VI
In Vivo; 2004; 18(2):107-12. PubMed ID: 15113036
[TBL] [Abstract][Full Text] [Related]
3. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961).
Panosyan EH; Grigoryan RS; Avramis IA; Seibel NL; Gaynon PS; Siegel SE; Fingert HJ; Avramis VI
Anticancer Res; 2004; 24(2C):1121-5. PubMed ID: 15154634
[TBL] [Abstract][Full Text] [Related]
4. Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor.
Asselin BL; Lorenson MY; Whitin JC; Coppola DJ; Kende AS; Blakley RL; Cohen HJ
Cancer Res; 1991 Dec; 51(24):6568-73. PubMed ID: 1742729
[TBL] [Abstract][Full Text] [Related]
5. An isocratic fluorescence HPLC assay for the monitoring of l-asparaginase activity and l-asparagine depletion in children receiving E. colil-asparaginase for the treatment of acute lymphoblastic leukaemia.
Nath CE; Dallapozza L; Eslick AE; Misra A; Carr D; Earl JW
Biomed Chromatogr; 2009 Feb; 23(2):152-9. PubMed ID: 18823071
[TBL] [Abstract][Full Text] [Related]
6. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.
Vieira Pinheiro JP; Wenner K; Escherich G; Lanvers-Kaminsky C; Würthwein G; Janka-Schaub G; Boos J
Pediatr Blood Cancer; 2006 Jan; 46(1):18-25. PubMed ID: 15929133
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007.
Schrey D; Borghorst S; Lanvers-Kaminsky C; Hempel G; Gerss J; Möricke A; Schrappe M; Boos J
Pediatr Blood Cancer; 2010 Jul; 54(7):952-8. PubMed ID: 20108339
[TBL] [Abstract][Full Text] [Related]
8. Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia.
Wenner KA; Vieira Pinheiro JP; Escherich G; Wessalowski R; Jorch N; Wolff J; Stehn M; Kohlschütter A; Boos J; Janka-Schaub GE
Klin Padiatr; 2005; 217(6):321-6. PubMed ID: 16307417
[TBL] [Abstract][Full Text] [Related]
9. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
Jarrar M; Gaynon PS; Periclou AP; Fu C; Harris RE; Stram D; Altman A; Bostrom B; Breneman J; Steele D; Trigg M; Zipf T; Avramis VI
Pediatr Blood Cancer; 2006 Aug; 47(2):141-6. PubMed ID: 16425271
[TBL] [Abstract][Full Text] [Related]
10. [Research on the pharmacokinetics and pharmacodynamics of L-asparaginase during its treatment of childhood acute lymphoblastic leukemia].
Chen FX; Cui YQ; Wu ZL; Ye TZ; Lai YH; Zou YW; Lu CY; Guan JM; Wei FG; Zhang H
Zhonghua Xue Ye Xue Za Zhi; 2005 Feb; 26(2):100-2. PubMed ID: 15921627
[TBL] [Abstract][Full Text] [Related]
11. l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial.
Domenech C; Thomas X; Chabaud S; Baruchel A; Gueyffier F; Mazingue F; Auvrignon A; Corm S; Dombret H; Chevallier P; Galambrun C; Huguet F; Legrand F; Mechinaud F; Vey N; Philip I; Liens D; Godfrin Y; Rigal D; Bertrand Y
Br J Haematol; 2011 Apr; 153(1):58-65. PubMed ID: 21332712
[TBL] [Abstract][Full Text] [Related]
12. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.
Rizzari C; Citterio M; Zucchetti M; Conter V; Chiesa R; Colombini A; Malguzzi S; Silvestri D; D'Incalci M
Haematologica; 2006 Jan; 91(1):24-31. PubMed ID: 16434367
[TBL] [Abstract][Full Text] [Related]
13. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.
Henriksen LT; Nersting J; Raja RA; Frandsen TL; Rosthøj S; Schrøder H; Albertsen BK;
Br J Haematol; 2014 Jul; 166(2):213-20. PubMed ID: 24702187
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of native Escherichia coli asparaginase.
Borghorst S; Pieters R; Kuehnel HJ; Boos J; Hempel G
Pediatr Hematol Oncol; 2012 Mar; 29(2):154-65. PubMed ID: 22376019
[TBL] [Abstract][Full Text] [Related]
16. A fluorometric assay for L-asparaginase activity and monitoring of L-asparaginase therapy.
Ylikangas P; Mononen I
Anal Biochem; 2000 Apr; 280(1):42-5. PubMed ID: 10805519
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase.
Asselin BL; Ryan D; Frantz CN; Bernal SD; Leavitt P; Sallan SE; Cohen HJ
Cancer Res; 1989 Aug; 49(15):4363-8. PubMed ID: 2743326
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and drug monitoring of L-asparaginase treatment.
Boos J
Int J Clin Pharmacol Ther; 1997 Mar; 35(3):96-8. PubMed ID: 9088996
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
[TBL] [Abstract][Full Text] [Related]
20. Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy.
Li YT; Kwon YM; Spangrude GJ; Liang JF; Chung HS; Park YJ; Yang VC
J Biomed Mater Res A; 2009 Oct; 91(1):209-20. PubMed ID: 18814276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
